Intranasal Bird Flu Vaccine: Broad Immunity – Vax-Before-Travel
Promising Intranasal Vaccine Shows Broad Immune Response Against H5N1 Bird Flu
Table of Contents
Global Health Risk and Vaccine growth
The ongoing spread of H5N1 influenza (bird flu) in animals, with documented cases of transmission too humans, continues to pose a significant global health threat. Researchers are actively developing vaccines to combat this serious issue.
university of Maryland Study Reveals Positive Results
Researchers at the University of Maryland School of medicine’s Center for Vaccine Development and Global health announced encouraging results from an early-phase clinical trial on November 6, 2025. The trial investigated an experimental intranasal vaccine, NanoVax H5, and its ability to trigger a broad immune response against multiple strains of H5N1 as published in Nature Communications.
The study, funded by a grant from the National Institutes of Allergy and Infectious Diseases, highlights the potential of mucosal immunization – administering vaccines through the nostrils – to enhance immune defenses against diverse influenza strains.
Safety, Immune Priming, and Broad Strain Recognition
The NanoVax H5 intranasal vaccine was found to be both safe and well-tolerated by participants. Crucially, individuals who received the boosted nasal vaccine demonstrated strong immune “priming,” meaning their immune systems were activated and prepared to respond effectively when afterward given a single dose of an intramuscular H5 flu shot.
Notably, the NanoVax H5 vaccine, even without a booster, triggered both mucosal and systemic immune defenses – a feat not previously achieved in clinical trials with other intranasal recombinant H5 flu vaccines.
“The vaccine also helped the immune system recognize multiple versions of the H5N1 virus, which is key because there are different versions of the virus and they change over time,” explained study co-lead author Meagan E. Deming, MD, PhD, Assistant Professor of Medicine at the University of Maryland School of Medicine (UMSOM), in a press release.
Potential for Lower Doses and Increased Vaccine Availability
Researchers suggest the use of an adjuvant in the vaccine formulation may allow for lower doses, potentially expanding the availability of vaccine stocks during an outbreak.This could be critical in ensuring broader access to protection in the event of a widespread H5N1 pandemic.